SCHEMBL1780911

SCHEMBL1780911

O=C(Nc1cc(-c2cccc3[nH]ccc23)cc2[nH]ncc12)c1cccc(=O)[nH]1

nearest known ligand 0.69

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PIK3CD O00329 10/20 0.69
PIK3CB P42338 8/20 0.69
PIM1 P11309 7/20 0.69
GSK3B P49841 7/20 0.69
PIK3CG P48736 7/20 0.69
PIK3CA P42336 7/20 0.69
NPC1 O15118 2/20 0.41
HTT P42858 2/20 0.41
RAB9A P51151 2/20 0.41
LMNA P02545 1/20 0.41
CYP1A2 P05177 1/20 0.41
CYP3A4 P08684 1/20 0.41
HPGD P15428 1/20 0.41
CYP2C19 P33261 1/20 0.41
HPGDS O60760 4/20 0.41
DHPS P49366 1/20 0.40
AURKA O14965 1/20 0.39
ROCK2 O75116 1/20 0.39
ERBB2 P04626 1/20 0.39
CSF1R P07333 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1119169 0.86 PIK3CD (0.77) PIK3CDPIK3CBPIM1GSK3BPIK3CG
SCHEMBL456388 0.86 PIK3CD (0.70) PIK3CDPIK3CBPIM1GSK3BPIK3CG
SCHEMBL462955 0.84 PIK3CD (0.68) PIK3CDPIK3CBPIM1GSK3BPIK3CG
SCHEMBL457703 0.83 PIK3CD (0.70) PIK3CDPIK3CBPIM1GSK3BPIK3CG
SCHEMBL2165967 0.82 PIK3CD (0.71) PIK3CDPIK3CBPIM1GSK3BPIK3CG
SCHEMBL459117 0.82 PIK3CD (1.00) PIK3CDPIK3CBPIM1GSK3BPIK3CG
SCHEMBL2216456 0.82 PIK3CD (0.76) PIK3CDPIK3CBPIM1GSK3BPIK3CG
SCHEMBL2212029 0.82 PIK3CD (0.73) PIK3CDPIK3CBPIM1GSK3BPIK3CG
SCHEMBL2212561 0.82 PIK3CD (0.76) PIK3CDPIK3CBPIM1GSK3BPIK3CG
SCHEMBL2214861 0.81 PIK3CD (0.65) PIK3CDPIK3CBPIM1GSK3BPIK3CG

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8765743-B2 Compounds GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) 2014-07-01 US claimed
US-20110118246-A1 Novel Compounds GLAXO GROUP LIMITED (GB) 2011-05-19 US claimed
US-9326987-B2 Indazole derivatives for use in the treatment of influenza virus infection GLAXO GROUP LIMITED (GB) 2016-05-03 US disclosed
US-8765743-B2 Compounds GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) 2014-07-01 US disclosed
US-20130165433-A1 Novel Use GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) 2013-06-27 US disclosed
US-20110118246-A1 Novel Compounds GLAXO GROUP LIMITED (GB) 2011-05-19 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130165433-A1 Novel Use HAVCR2, MAVS, ENTPD5 PIK3CD 2938/4885PIK3CB 1706/4885PIM1 1258/4885
US-20110118246-A1 Novel Compounds PIK3CA, PIK3C2B, PIK3CD PIK3CD 3/4885PIK3CB 4/4885PIM1 68/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.